AzTrials
AzTrials

Bronchopulmonary Dysplasia (BPD)NCT04756297

Lung Ultrasound for Prediction of Bronchopulmonary Dysplasia

An observational study of Bronchopulmonary Dysplasia (BPD), run by Adel Mohamed at 2 sites in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Extreme preterm infants (GA ≤ 28+6 weeks) are at high risk for bronchopulmonary dysplasia (BPD) that has been associated with significant long-term impairment. Lung ultrasound score (LUSs) has the potential to early identify infants at high risk of developing BPD who may benefit from early intervention. Read more about this study

Who is it for?
Any age
Conditions the study is for
Bronchopulmonary Dysplasia (BPD)
How many people
152 participants
Where
2 sitesCanada
Study dates
1 Jul 2019to 25 Feb 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: All infants who are born at GA ≤ 28+6 weeks will be enrolled in the study after obtaining REB approval and parents' consent.

Who may be able to join

  • GA ≤ 28+6 weeks Admitted to the NICU at Mount Sinai Hospital or Health sciences Centre-Winnipeg consent obtained.

Who cannot join

  • Infants who are born at > 28 weeks GA, or have congenital or chromosomal abnormalities, or parents declined consent will be excluded.
  • -

Trial locations and contacts

2 sites in 1 country.

Canada2 sites
  • Mount Sinai Hospital

    Toronto, Ontario, M5G1X5

  • Health Sciences Centre

    Winnipeg, Manitoba, R3C3H8

Other trials in Canada

About this study

Official title: Lung Ultrasound for Prediction of Bronchopulmonary Dysplasia in Extremely Preterm Neonates: A Prospective Diagnostic Cohort Study

Extreme preterm infants (GA ≤ 28+6 weeks) are at high risk for bronchopulmonary dysplasia (BPD) that has been associated with significant long-term impairment. Lung ultrasound score (LUSs) has the potential to early identify infants at high risk of developing BPD who may benefit from early intervention.

Aim: To assess if LUS score can be utilized to predict the development of BPD in infants born at ≤ 28+6 weeks, early in their postnatal course, when the disease is likely to be most amenable to therapeutic intervention.

Read the detailed description

Background and Importance: Despite advances in neonatal care and improved survival among immature infants, bronchopulmonary dysplasia (BPD) remained a serious complication among preterm neonates born at <29 weeks' gestational age. A variety of therapies including antenatal steroid, surfactant administration, high-frequency ventilation, postnatal steroid (systemic and inhaled), and vitamin A supplementation have been studied as means to prevent BPD. Ideally, interventional studies aim to prevent or reduce BPD should include criteria for selecting infants at highest risk for BPD while excluding infants at low risk. Recently, Lung ultrasound severity score (LUSs) has shown in few studies to be a promising tool for assessing lung aeration and for early prediction of preterm infants with evolving BPD. These studies have a major limitation as it includes infants at low risk for BPD (> 28 weeks gestational age). In this study, we will assess the accuracy of LUSs for early identification BPD among extreme preterm infants born at <29 weeks' GA.

Study procedure In this prospective observational study, our aim is to recruit a large cohort of extreme premature neonates (born at ≤ 28+6 weeks gestational age), and sequentially perform an "early-diagnostic assessments "on day 3 of age. Subsequent LUS assessment will be performed at 7 days (+/- 1 day) of age and the third LUS assessment will be at 14 (+/-2 days of age). Assessment will be done in the same manner as described by Cattarossi et.al. Basically, each lung will be divided into 3 zones (upper anterior, lower anterior, and lateral) and will be examined using a L20 linear probe to perform a longitudinal lung scan (Fig 1). Additionally, we will score each zone (score 0-to 3 points) according to the modified LUS score by Brat et.al [20]. Based on the LUS pattern in each lung zone the total score can range from 0 to 18 for the 6 zones of both lungs. As summarized in figure 2 the LUS score will include signs that can be used to diagnose TTN, RDS or identify early changes of BPD.

We will record this data for babies enrolled in the study, along with their relevant medical data. At the end of this study, we will divide the cohort into those who developed BPD and those who did not as per currently used standard criteria and will compare the results of new LUS severity score obtained at earlier time points. Prediction models will be created including variables associated with BPD development at each time point with and without inclusion of lung US severity score.

Regarding LUS assessment a Zonare Ultrasound machine (Z.One PRO ultrasound) with a high-frequency (L20-5) linear probe will be used. This high-frequency probe gives excellent resolution and adequate penetration in these small infants. We decided to start LUS scanning at day 3 of age as most of these babies are at risk for intraventricular hemorrhage and minimal handling especially during the first 3 days is highly recommended.

All LUS assessments will be undertaken at the same time using a standard aseptic technique and without too much handling of the infants. Approval will be obtained from the Research Ethics Board (REB) at Sinai Health System and Health sciences Centre-Winnipeg. Parents will be approached for consent before enrollment.

Medical subject headings
Bronchopulmonary Dysplasia

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Assess accuracy of LUSs for early identification of BPD in extreme preterm infants

    The primary outcome of this study is to assess predictive characteristics of LUS score: Sensitivity, specificity, positive and negative predictive value, likelihood ratio and c-statistics of LUS score. Assessment of BPD at 36 weeks will be done as per currently used standard criteria for BPD.

    The primary outcome of this study is to assess predictive characteristics of LUS score: Sensitivity, specificity, positive and negative predictive value, likelihood ratio and c-statistics of LUS score. Assessment of BPD at 36 weeks will be done as per currently used standard criteria for BPD.

    LUS will be conducted at D3, 7 and 14 of life

    Measured: 2 weeks after birth

Secondary outcomes (1)
  1. Assess predictive characteristics of LUS score integration in clinical variables derived model to see which model has higher predictive characteristics

    Different predictive models will be constructed to identify which model best predict BPD

    Measured: 2 WEEKS

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Feb 2021
  2. Study start1 Jul 2019
  3. Primary completion25 Feb 2021
  4. Study completion25 Feb 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
152 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04756297
Sponsor's protocol ID
19-0072-E
Status last verified
Mar 2021
First submitted
11 Feb 2021
Last updated
1 Apr 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Mohamed A, Mohsen N, Diambomba Y, Lashin A, Louis D, Elsayed Y, Shah PS. Lung Ultrasound for Prediction of Bronchopulmonary Dysplasia in Extreme Preterm Neonates: A Prospective Diagnostic Cohort Study. J Pediatr. 2021 Nov;238:187-192.e2. doi: 10.1016/j.jpeds.2021.06.079. Epub 2021 Jul 6.

    PubMed 34237347

Questions about this trial

What is this clinical trial studying?

An observational study of Bronchopulmonary Dysplasia (BPD), run by Adel Mohamed at 2 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Assess accuracy of LUSs for early identification of BPD in extreme preterm infants (time frame: 2 weeks after birth). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04756297, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in